Search Results
Your search for this matches 25286 pages
Showing 4201 - 4250
Shannon N. Westin, MD, MPH, on Endometrial and Ovarian Cancers: New Data on Selumetinib and Olaparib From the SOLAR Trial
Shannon N. Westin, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses new findings on the combination of olaparib and selumetinib, which benefited patients with RAS-mutant ovarian and endometrial cancers. This combination will be explored further in these select cohorts in the ...
Addressing Racial Disparities in Cancer Pain Management: A Potential Role for Music Therapy
Guest Editor’s Note: Despite its high prevalence, cancer pain remains undertreated. Racial disparities present further challenges to assessing and managing pain. Music therapy, a nonpharmacologic intervention, has been documented to be effective in controlling cancer pain. In this article, Kevin T. ...
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
As reported in JAMA Oncology by Tang et al, the phase II EXTEND (External Beam Radiation to Eliminate Nominal Metastatic Disease) trial has shown that the addition of metastasis-directed therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic...
MRD and KMT2A Fusion Partners in Predicting Outcomes of Childhood KMT2A-Rearranged Acute Myeloid Leukemia
In a retrospective study reported in the Journal of Clinical Oncology, van Weelderen et al, of the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG), found that KMT2A fusion partners and measurable residual disease (MRD) at end of induction phase 2 were independent predictors of...
Addition of Abiraterone Acetate and Prednisone to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Michael J. Morris, MD, and colleagues, the phase III Alliance A031201 trial has shown no significant improvement in overall survival with the addition of abiraterone acetate and prednisone to enzalutamide as first-line treatment for metastatic...
NCCN 2023 Annual Conference: Quality-of-Life Issues
The National Comprehensive Cancer Network (NCCN) held its annual meeting recently in Orlando. On this week’s episode of <em>The ASCO Post Podcast</em>, we’ll hear from two presenters who discussed quality of life issues in individuals with cancer.
Pathologic Complete Response and Outcomes in Localized Soft-Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy
In an analysis reported in JAMA Oncology, Wang et al found that pathologic complete response (pCR) was associated with improved outcomes among patients with localized soft-tissue sarcoma receiving neoadjuvant chemoradiotherapy or radiotherapy. The analysis included data from patients from two RTOG...
Update on Withdrawal of Ibrutinib Accelerated Approvals for MCL and MZL in the United States
AbbVie announced that it intends to voluntarily withdraw, in the United States, accelerated ibrutinib (Imbruvica) approvals for patients with mantle cell lymphoma (MCL) who have received at least one prior therapy as well as patients with marginal zone lymphoma (MZL) who require systemic therapy...
Pragmatica-Lung Trial Begins Enrolling Patients With NSCLC Who Did Not Respond to Previous Therapy
The National Cancer Institute (NCI) announced that it has helped launch the randomized phase III Pragmatica-Lung trial examining the efficacy of ramucirumab plus pembrolizumab in treating patients with advanced non–small cell lung cancer (NSCLC). The new study is one of the first NCI-supported...
Digital Breast Tomosynthesis May Improve Breast Cancer Screening Performance in Community Settings
Researchers have found that digital breast tomosynthesis may have improved breast cancer screening performance in community practices and could be effective at identifying more invasive cancers compared with digital mammography, according to a new study published by Lee et al in Radiology. The...
Statewide Survey May Provide Insight Into Cancer-Related Knowledge, Beliefs, and Behaviors of Hispanic Individuals in Indiana
A new survey of Hispanic adults residing in Indiana may present a snapshot of their cancer-related knowledge, beliefs, and behaviors and provide guidance for the future development of tailored cancer screening messaging and prevention strategies, according to a study published by Espinoza-Gutarra...
Cancer Susceptibility Germline Pathogenic Variants Among Older Patients
Hereditary cancer syndromes are caused by a pathogenic variant in cancer susceptibility genes, which overall account for approximately 10% of all cancers. Carriers of pathogenic variants are at an increased risk of developing cancer during their lifetime. Genomic cancer risk assessment makes it...
Novel Device May Be Safe, Effective Chemotherapy Delivery System for Patients With Muscle-Invasive Bladder Cancer Who Are Unfit for Standard Therapy
Researchers have found that the novel intravesical chemotherapy delivery system TAR-200 may be safe and effective for patients with advanced muscle-invasive bladder cancer who are medically unfit for standard treatment, according to a new study published by Tyson et al in The Journal of Urology....
Financial Toxicity of Cancer May Impact Partner’s Quality of Life
Researchers have discovered that the financial impact of an individual’s cancer diagnosis may also impact a partner’s health-related quality of life, according to a new study published by Ghazal et al in JAMA Network Open. “When you think of key developmental milestones young adults expect to...
Prior CTLA-4 Inhibition May Influence Response to PD-1 Inhibitors in Patients With Advanced Melanoma
Researchers have found that responses to PD-1 inhibitor treatment in patients with advanced melanoma may depend on whether they had received previous treatment with CTLA-4 inhibitors, according to a new study published by Campbell et al in Cancer Cell. “In our large set of data, features that have...
Combination Therapy May Help Patients With KMT2A-Mutated ALL or AML Overcome BET Inhibitor Resistance
Researchers have developed a novel combination therapy approach to help patients with KMT2A-mutated acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) overcome resistance to bromodomain and extraterminal domain (BET) inhibitors without adding toxicity, according to a novel study...
Study Finds Precursor Pancreatic Lesions Occur Frequently in Healthy Human Pancreases
Pancreatic cancer is a rare disease, accounting for about 3% of all cancers in the United States. It is the deadliest of all solid malignancies, accounting for about 7% of all cancer deaths each year, and carries a 5-year survival rate of just 11.5%. According to the American Cancer Society, in...
Mortality After Colonoscopy-Detected vs Postcolonoscopy-Diagnosed Colorectal Cancer in the VA Health-Care System
In a study reported in JAMA Network Open, Kahi et al found no differences in all-cause or cancer-specific mortality among veterans in the Veterans Affairs (VA) health-care system with colonoscopy-detected colorectal cancer vs those with postcolonoscopy-diagnosed colorectal cancer. Study Details...
Highlights From the NCCN 2023 Annual Conference
The National Comprehensive Cancer Network (NCCN) held its annual meeting recently in Orlando. On this week’s episode, we’ll hear from two of the presenters who discussed updates to the NCCN Clinical Practice Guidelines in Oncology in chronic lymphocytic leukemia/small lymphocytic lymphoma and CNS...
Azacitidine in Combination With Trametinib May Be Effective for Pediatric Patients With JMML
Researchers have found that the hypomethylating agent azacitidine plus the MEK inhibitor trametinib may be a promising new combination to treat patients with juvenile myelomonocytic leukemia (JMML), according to a preclinical study published by Pasupuleti et al in Molecular Therapy. Background JMML ...
Healthy Lifestyles May Be Associated With Reduced Mortality Risk in Pediatric Cancer Survivors
Researchers have provided strong evidence that a healthy lifestyle may significantly reduce mortality in adults who have survived pediatric cancer, according to a new study published by Dixon et al in The Lancet. The findings are among the first to reveal that the specific primary causes of...
Researchers Identify Potential Biomarkers of Response to Immunotherapy in Patients With Renal Cell Carcinoma
Researchers have revealed that the number of tumor-infiltrating lymphocytes, the state of necrosis, and mutations to the tumor-suppressor gene PBRM1 form a biomarker signature that may predict how patients with renal cell carcinoma will respond to immunotherapy, according to a novel study published ...
City of Hope to Rebrand Cancer Treatment Centers of America Locations to Reflect Transition to National System
City of Hope in Duarte, California, recently announced that its subsidiary, Cancer Treatment Centers of America (CTCA), will fully transition its clinical locations to City of Hope’s brand. CTCA locations in different cities will now be called City of Hope Atlanta, City of Hope Chicago, and City of ...
Surgeon and Cancer Researcher Kelly M. McMasters, MD, PhD, Celebrates the ‘Miracle of Translational Science’
In this installment of our Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kelly M. McMasters, MD, PhD, who, for the past 27 years, has directed a basic and translational science lab studying adenovirus-mediated cancer gene therapy and melanoma biomarkers....
Elizabeth M. Jaffee, MD, FAACR, to Receive 2023 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
The American Association for Cancer Research (AACR) will honor Elizabeth M. Jaffee, MD, FAACR, AACR Past President, with the 2023 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the 2023 AACR Annual Meeting, to be held on April 14–19 in Orlando,...
Nobel Laureate Carolyn R. Bertozzi, PhD, to Receive 2023 AACR Award for Outstanding Achievement Cancer Research
The American Association for Cancer Research (AACR) will honor Nobel Laureate Carolyn R. Bertozzi, PhD, with the 2023 AACR Award for Outstanding Achievement in Chemistry in Cancer Research during the 2023 AACR Annual Meeting on April 14–19 in Orlando, Florida. Dr. Bertozzi’s award lecture will be...
Yes, You Should Attend the 2023 ASCO Annual Meeting
The questions I am challenged to answer are twofold: (1) Should you attend the 2023 ASCO Annual Meeting? (2) If you attend, how is your time best spent? Most people agree scientific conferences are important venues for cancer researchers and clinicians to share and discuss research findings,...
Genetics Likely Caused My Small Cell Lung Cancer
When I was diagnosed with lung cancer, in 2007, I asked the physician not to tell me the type, stage, or prognosis. I was about to start nursing school and was aware enough about the disease to know that not many people survived. I’ve since discovered that I had stage 3B small cell lung cancer,...
Abemaciclib Expanded Indication for Adjuvant Use in HR-Positive, HER2-Negative, Node-Positive Early Breast Cancer
On March 3, 2023, abemaciclib was approved for use with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of patients with hormone receptor (HR)-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence.1 Abemaciclib was previously approved...
Heavy Toll From Prior Authorization Exceeds Alleged Benefits, According to AMA Survey
The approval process health insurers impose on medical services or drugs is generating a toll that exceeds the purported benefits, according to a physician survey recently released by the American Medical Association (AMA) and shared in a letter to federal health officials.1 Although health...
EAU and ASCO Release Collaborative Guidelines on Penile Cancer
Penile cancer is a rare disease with an incidence that is rising globally. Driven by a goal to offer clinicians and patients guidance on the management of this rare condition, ASCO collaborated with the European Association of Urology (EAU) to develop new guidelines on its diagnosis and treatment....
Kerin Adelson, MD, Named MD Anderson Chief Quality and Value Officer
The University of Texas MD Anderson Cancer Center has announced the appointment of Kerin Adelson, MD, as the institution’s Chief Quality and Value Officer. An accomplished clinician and researcher with extensive leadership experience in cancer care, Dr. Adelson will also hold a faculty appointment...
Summing It Up: Neoadjuvant Therapy in Triple-Negative Disease
Here is how Dr. Sharma summed up the current state of neoadjuvant therapy in triple-negative breast cancer: The addition of an immune checkpoint inhibitor to neoadjuvant chemotherapy improves long-term outcomes. This strategy can produce a modest improvement in pathologic complete response and a...
Lymphoma Research Foundation Establishes Kanti R. Rai, MD, Clinical Scholar Program for the Ongoing Study of CLL
The Lymphoma Research Foundation (LRF) has announced the creation of the Kanti R. Rai, MD, Clinical Scholar Program to fund the ongoing study of lymphoma and chronic lymphocytic leukemia (CLL). Established in recognition of the global leadership of Kanti R. Rai, MD, in the field of lymphoma and CLL ...
Which Patients With Breast Cancer Can Omit Radiotherapy?
Although advances in radiation therapy have rendered this treatment modality more tolerable, they have not completely eliminated the burden of radiation-related toxicity. In an ideal setting, clinicians would be able to identify patients whose risk of recurrence is sufficiently low that they can...
Early-Stage Triple-Negative Breast Cancer: Optimizing Therapy
The management of early-stage triple-negative breast cancer has been evolving at a fast pace, thanks largely to the discovery that immune checkpoint blockade can be effective in this subtype. At the 2023 Miami Breast Cancer Conference, Priyanka Sharma, MD, Professor of Medicine, University of...
Expert Point of View: Callisia N. Clarke, MD, MS, FACS, FSSO
Moderator of the press conference at the 2023 International Conference on Surgical Cancer Care, Callisia N. Clarke, MD, MS, FACS, FSSO, Assistant Professor of Surgery at the Medical College of Wisconsin, highlighted the significance of the 80% response rates to neoadjuvant immunotherapy in primary...
Neoadjuvant Pembrolizumab in Desmoplastic Melanoma
Neoadjuvant pembrolizumab may significantly improve the management of desmoplastic melanoma, increasing the likelihood of successful resection and reducing the need for further surgery or radiation therapy, according to the response data presented at the 2022 ASCO Annual Meeting, with the surgical...
Highlights of Novel Therapies Under Study in Genitourinary Cancers
Here are some brief reports from the 2023 ASCO Genitourinary (GU) Cancers Symposium that we hope are of interest. They include real-world evidence about the use of avelumab maintenance in metastatic urothelial carcinoma, data on the feasibility of sequencing radium-223 and Lu-177–PSMA-617 in...
Study Examines Utility, Accuracy of ChatGPT in Offering Breast Cancer Screening Recommendations
A new study suggests that the answers generated by the artificial intelligence (AI) chatbot ChatGPT may provide correct breast cancer screening advice the vast majority of the time; however, the information is sometimes inaccurate or even fictitious, according to the report published by Haver et al ...
Interferon Alfa-2b May Substantially Increase Survival in Patients With Lymphomatoid Granulomatosis
Researchers have demonstrated that patients with low-grade lymphomatoid granulomatosis who were treated with the immunotherapy interferon alfa-2b may survive for a median of 20 years after diagnosis, according to a novel study published by Melani et al in The Lancet Haematology. The findings...
Training Oncology Nurses on Primary Palliative Care May Improve End-of-Life Care and Spur Creation of Advance Directives for Patients With Cancer
Specially trained oncology infusion room nurses may be capable of improving advance care planning for patients with advanced cancer at the end of life, according to a new study published by Cohen et al in JNCCN—Journal of the National Comprehensive Cancer Network. Background “Advance care planning...
Addressing Health Disparities in Oncology Care—Legally and Ethically
A health disparity is typically defined as involving a differential in health outcomes between some groups of patients and other groups, for example, between White and Black patients, in which some groups fare better than others. Health inequities are commonly defined as health differences that...
Expert Point of View: Oliver Sartor, MD
The results of recent trials of PARP (poly [ADP-ribose] polymerase) inhibitor plus second-generation androgen receptor inhibitor combinations have had varying results in metastatic castration-resistant prostate cancer. Some trials suggest the benefit is confined to those with BRCA mutations and/or...
Deductibles, Copays May Discourage Patients From Receiving Follow-up Breast Cancer Screenings
Researchers found that 20% of patients attending breast cancer screening appointments were likely to skip additional testing after abnormal findings on their mammograms if there was a deductible or copayment involved, according to a new study published by Ngo et al in Radiology. Background...
Addition of Toripalimab to Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
In a Chinese single-center phase II trial (EC-CRT-001) reported in The Lancet Oncology, Zhu et al found that the addition of the PD-1 inhibitor toripalimab to definitive chemoradiotherapy resulted in “encouraging activity and acceptable toxicity” in patients with locally advanced esophageal...
Risk of Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer
In a phase II trial (ACOSOG Z11102/Alliance) reported in the Journal of Clinical Oncology, Judy C. Boughey, MD, and colleagues found that breast-conserving therapy was associated with a low rate of local recurrence in women with multiple ipsilateral breast cancer sites. Study Details A total of 204 ...
HHS Releases National Cancer Plan to Advance the Goals of the Cancer Moonshot and Improve Outcomes for All Patients
On April 3, the U.S. Department of Health and Human Services (HHS) released a National Cancer Plan, which calls for collaboration to realize the objectives laid out in the Cancer Moonshot to reduce cancer mortality by at least 50% over the next 25 years and “end cancer as we know it.” Developed by...
FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv/Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
On April 3, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the antibody-drug conjugate enfortumab vedotin-ejfv (Padcev) in combination with the PD-1 inhibitor pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are...
Pathologic Complete Responses May Be Prognostic of Outcomes for Patients With Soft-Tissue Sarcoma
Researchers have discovered that pathologic complete responses may be associated with improved survival outcomes for patients with localized soft-tissue sarcoma who received preoperative chemoradiotherapy or radiotherapy, according to a novel study published by Wang et al in JAMA Oncology. The new...
